

USSN: 10/743,109

- 3 -


PC20612A

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound of the formula I:



or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein

- (a) each occurrence of Z is independently  $\text{CH}_2$ ,  $\text{CH}=\text{CH}$ , or phenyl, where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then m is 1;
- (b) G is  $(\text{CH}_2)_x$ , where x is 1-7,  $\text{CH}_2\text{CH}=\text{CHCH}_2$ ,  $\text{CH}=\text{CH}$ ,  $\text{CH}_2\text{-phenyl-CH}_2$ , or phenyl;
- (c)  $\text{W}^1$  and  $\text{W}^2$  are independently L, V,  $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$ , or  $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{V}$  where c is 1 or 2 and n is an integer ranging from 0 to 7;
- (d) each occurrence of  $\text{R}^1$  or  $\text{R}^2$  is independently  $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkenyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkynyl}$ , phenyl, or benzyl or when one or both of  $\text{W}^1$  and  $\text{W}^2$  is  $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$ , then  $\text{R}^1$  and  $\text{R}^2$  can both be H to form a methylene group; or  $\text{R}^1$  and  $\text{R}^2$  and the carbon to which they are both attached are taken together to form a  $(\text{C}_3\text{-}\text{C}_7)\text{cycloakyl}$  group;
- (e)  $\text{R}^3$  is H,  $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkenyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkynyl}$ ,  $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ , phenyl, benzyl, Cl, Br, CN,  $\text{NO}_2$ , or  $\text{CF}_3$ ;
- (f)  $\text{R}^4$  is OH,  $(\text{C}_1\text{-}\text{C}_6)\text{alkyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkenyl}$ ,  $(\text{C}_2\text{-}\text{C}_6)\text{alkynyl}$ ,  $(\text{C}_1\text{-}\text{C}_6)\text{alkoxy}$ , phenyl, benzyl, Cl, Br, CN,  $\text{NO}_2$ , or  $\text{CF}_3$ ;


USSN: 10/743,109

- 4 -


PC20612A

(g) L is  $C(R^1)(R^2)-(CH_2)_n-Y$ , wherein n is an integer from 0 to 5;

(h) V is:




(i) each occurrence of Y is independently (C<sub>1</sub>-C<sub>6</sub>)alkyl, OH, COOH, COOR<sup>5</sup>, SO<sub>3</sub>H,



USSN: 10/743,109

- 5 -

PC20612A



wherein:

(i)  $R^5$  is  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH,  $(C_1-C_6)$ alkoxy, or phenyl groups,

(ii) each occurrence of  $R^6$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl and is unsubstituted or substituted with one or two halo, OH,  $(C_1-C_6)$ alkoxy, or phenyl groups;

(iii) each occurrence of  $R^7$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl; and

(j) X is  $(CH_2)_z$  or Ph, wherein z is an integer from 0 to 4.

Claim 2 (original): The compound of claim 1, wherein G is  $(CH_2)_2$ .

Claim 3 (original): The compound of claim 1, wherein each occurrence of  $Z_m$  is independently  $(CH_2)$  and m is 1-4.

Claim 4 (original): The compound of claim 1, wherein each occurrence of  $W^1$  and  $W^2$  is independently L.

Claim 5 (original): The compound of claim 2, wherein L is  $C(CH_3)_2-(CH_2)-OH$ .


USSN: 10/743,109

- 6 -


PC20612A

**Claim 6 (original):** The compound of claim 1, wherein each occurrence of W<sup>1</sup> and W<sup>2</sup> is independently v.

**Claim 7 (original):** The compound of claim 6, wherein V is



**Claim 8 (currently amended):** A compound of the formula II:

**II**



or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

- (a) each occurrence of Z is independently CH<sub>2</sub> or CH=CH, wherein each occurrence of m is independently an integer ranging from 1 to 9;
- (b) Q is (CH<sub>2</sub>)<sub>x</sub>, CH<sub>2</sub>CH=CHCH<sub>2</sub>, or CH=CH, where x is 2, 3, or 4;
- (c) W<sup>1</sup> and W<sup>2</sup> are independently L, V, or C(R<sup>1</sup>)(R<sup>2</sup>)-(CH<sub>2</sub>)<sub>c</sub>-V, where c is 1 or 2;
- (d) each occurrence of R<sup>1</sup> and R<sup>2</sup> is independently (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, phenyl, benzyl, or R<sup>1</sup> and R<sup>2</sup> and the carbon to which they are both attached are taken together to form a (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl group;
- (e) L is C(R<sup>1</sup>)(R<sup>2</sup>)-(CH<sub>2</sub>)<sub>n</sub>-Y, where n is an integer ranging from 0 to 5;
- (f) V is:

USSN: 10/743,109

- 7 -

PC20612A

(g) each occurrence of Y is independently (C<sub>1</sub>-C<sub>6</sub>)alkyl, OH, COOH, COOR<sup>3</sup>, SO<sub>3</sub>H,

USSN: 10/743,109

- 8 -

PC20612A

**wherein:**

- (i)  $R^3$  is  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH,  $(C_1-C_6)$ alkoxy, or phenyl groups,
- (ii) each occurrence of  $R^4$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl and is unsubstituted or substituted with one or two halo, OH,  $(C_1-C_6)$ alkoxy, or phenyl groups; and
- (iii) each occurrence of  $R^5$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl; and

(h) X is  $(CH_2)_z$ , or Ph, wherein z is an integer from 0 to 4.

Claim 9 (original): The compound of claim 8, wherein each occurrence of  $W^1$  and  $W^2$  is independently L.

Claim 10 (original): The compound of claim 9, wherein L is  $C(CH_3)_2-(CH_2)_n-Y$ .

Claim 11 (original): The compound of claim 10, wherein each occurrence of Y is independently OH, COOR<sup>7</sup>, or COOH.

Claim 12 (currently amended): The compound of claim 8, wherein Q is CH=CH-.

Claim 13 (original): The compound of claim 8, wherein  $Z_m$  is CH<sub>2</sub> and m is 1 – 3.

Claim 14 (original): The compound of claim 8, wherein each of  $W^1$  and  $W^2$  is independently  $C(R^1)(R^2)-(CH_2)-V$ .

Claim 15 (original): The compound of claim 14, wherein  $R^1$  and  $R^2$  are each independently  $(C_1-C_6)$ alkyl.


Claim 16 (original): The compound of claim 15, wherein  $R^1$  and  $R^2$  are each methyl.

USSN: 10/743,109

- 9 -


PC20612A

Claim 17 (original): A compound of the formula III



or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:


- (a) each occurrence of  $m$  is independently an integer ranging from 1 to 9;
- (b)  $r$  is 2, 3, or 4;
- (c) each occurrence of  $n$  is independently an integer ranging from 0 to 7;
- (d) each occurrence of  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^{11}$ , and  $\text{R}^{12}$  is independently ( $\text{C}_1\text{-C}_6$ )alkyl, ( $\text{C}_2\text{-C}_6$ )alkenyl, ( $\text{C}_2\text{-C}_6$ )alkynyl, phenyl, benzyl, or  $\text{R}^1$  and  $\text{R}^2$  and the carbon to which they are both attached are taken together to form a ( $\text{C}_3\text{-C}_7$ )cycloalkyl group, or  $\text{R}^{11}$  and  $\text{R}^{12}$  and the carbon to which they are both attached are taken together to form a ( $\text{C}_3\text{-C}_7$ )cycloalkyl group; and
- (e) each occurrence of  $\text{Y}$  is independently ( $\text{C}_1\text{-C}_6$ )alkyl, OH, COOH,  $\text{COOR}^3$ ,  $\text{SO}_3\text{H}$ ,



USSN: 10/743,109

- 10 -

PC20612A



wherein:

- (i)  $R^3$  is  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH,  $(C_1-C_6)$ alkoxy, or phenyl groups;
- (ii) each occurrence of  $R^4$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl and is unsubstituted or substituted with one or two halo, OH,  $C_1-C_6$ alkoxy, or phenyl groups;
- (iii) each occurrence of  $R^5$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl, or  $(C_2-C_6)$ alkynyl; and
- (f) X is  $(CH_2)_z$  or Ph, wherein z is an integer from 0 to 4.


Claim 18 (original): The compound of claim 17, wherein each occurrence of  $Y^1$  and  $Y^2$  is independently OH,  $COOR^3$ , or COOH.

USSN: 10/743,109

- 11 -


PC2061...

Claim 19 (original): A compound of the formula IV




or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

- (a) each occurrence of  $m$  is an independent integer ranging from 1 to 9;
- (b)  $x$  is 2, 3, or 4;
- (c) each of  $\text{V}^1$  and  $\text{V}^2$  is independently:



Claim 20 (original): A compound of the formula V:



or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein:

- (a) each occurrence of  $Z$  is independently  $\text{CH}_2$ ,  $\text{CH}=\text{CH}$ , or phenyl, where each occurrence of  $m$  is independently an integer ranging from 1 to 5, but when  $Z$  is phenyl then its associated  $m$  is 1;


USSN: 10/743,109

- 12 -

PC20612A

(b) G is  $(CH_2)_x$ ,  $CH_2CH=CHCH_2$ ,  $CH=CH$ ,  $CH_2$ -phenyl- $CH_2$ , or phenyl, where x is an integer ranging from 1 to 7;

(c)  $W^1$  and  $W^2$  are independently  $C(R^8)(R^9)-(CH_2)_n-Y$ , where n is an integer ranging from 0 to 7;




(d) each occurrence of  $R^8$  and  $R^9$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, phenyl, or benzyl or  $R^8$  and  $R^9$  can be taken together to form a carbonyl group;

(e) each occurrence of  $R^1$  and  $R^2$  is independently H,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, phenyl, or benzyl or  $R^1$  and  $R^2$  can be taken together to form a carbonyl group or  $R^1$  and  $R^2$  and the carbon to which they are both attached are taken together to form a  $(C_3-C_7)$ cycloalkyl group;

(f) each occurrence of  $R^6$  and  $R^7$  is independently H,  $(C_1-C_6)$ alkyl, or  $R^6$  and  $R^7$  can be taken together to form a carbonyl group or  $R^6$  and  $R^7$  and the carbon to which they are both attached are taken together to form a  $(C_3-C_7)$ cycloalkyl group;


(g) Y is independently  $(C_1-C_6)$ alkyl, OH, COOH,  $COOR^3$ ,  $SO_3H$ ,



USSN: 10/743,109

- 13 -

PC20612A



wherein:

- (i) R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, or phenyl groups;
- (ii) each occurrence of R<sup>4</sup> is independently H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, or (C<sub>2</sub>-C<sub>6</sub>)alkynyl and is unsubstituted or substituted with one or two halo, OH, C<sub>1</sub>-C<sub>6</sub> alkoxy, or phenyl groups;
- (iii) each occurrence of R<sup>5</sup> is independently H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, or (C<sub>2</sub>-C<sub>6</sub>)alkynyl;
- (h) each occurrence of b is independently 0 or 1 or optionally the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds; and
- (i) X is (CH<sub>2</sub>)<sub>z</sub> or Ph, wherein z is an integer from 0 to 4.


USSN: 10/743,109

+  
- 14 -

PC20612A


**Claim 21 (original):** The compound of claim 20, wherein each occurrence of  $W^1$  and  $W^2$  is an independent  $C(R^1)(R^2)-(CH_2)_n-Y$  group and each occurrence of Y is independently OH, COOR<sup>3</sup>, or COOH.

**Claim 22 (original):** A compound of the formula VI:



or a pharmaceutically acceptable salt, hydrate, solvate, or a mixture thereof, wherein

- (a) each occurrence of m is independently an integer ranging from 1 to 5;
- (b) X is  $(CH_2)_z$  or Ph, wherein z is an integer from 0 to 4;
- (c)  $W^1$  and  $W^2$  are independently  $C(R^1)(R^2)-(CH_2)_n-Y$ , where n is an integer ranging from 0 to 7;




USSN: 10/743,109

- 15 -

PC20612A

(d) each occurrence of R<sup>1</sup> or R<sup>2</sup> is independently (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, or R<sup>1</sup> and R<sup>2</sup> and the carbon to which they are both attached are taken together to form a (C<sub>3</sub>-C<sub>7</sub>)cycloakyl group;

(e) Y is (C<sub>1</sub>-C<sub>5</sub>)alkyl, (CH<sub>2</sub>)<sub>n</sub>OH, (CH<sub>2</sub>)<sub>n</sub>COOH, (CH<sub>2</sub>)<sub>n</sub>COOR<sup>3</sup>, SO<sub>3</sub>H,



**whereto:**

- (i)  $R^3$  is ( $C_1$ - $C_6$ )alkyl, ( $C_2$ - $C_6$ )alkenyl, ( $C_2$ - $C_6$ )alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, ( $C_1$ - $C_6$ )alkoxy, or phenyl groups,
- (ii) each occurrence of  $R^4$  is independently H, ( $C_1$ - $C_6$ )alkyl, ( $C_2$ - $C_6$ )alkenyl, or ( $C_2$ - $C_6$ )alkynyl and is unsubstituted or substituted with one or two halo, OH,  $C_1$ - $C_6$  alkoxy, or phenyl groups,
- (iii) each occurrence of  $R^5$  is independently H, ( $C_1$ - $C_6$ )alkyl, ( $C_2$ - $C_6$ )alkenyl, or ( $C_2$ - $C_6$ )alkynyl;

USSN: 10/743,109


- 16 -

PC20612A


- (f) each occurrence of **b** is independently 0 or 1; and
- (g) **X** is  $(CH_2)_z$  or Ph, wherein **z** is an integer from 0 to 4.

**Claim 23 (currently amended):** The compound of claim 22, wherein each occurrence of **W1** and **W2** is independently  $C(R^1)(R^2)-(CH_2)_n-Y$ -groups and each occurrence of **Y** is independently OH,  $COOR^3$ , or COOH.


**Claim 24 (currently amended):** A compound of structure:



6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid;



2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol;



6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; and



2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol.

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,

**Claim 25 (original):** A pharmaceutical composition comprising a compound of claim 1, 8, 17, 19, 20, 22, or 24 and a pharmaceutically acceptable vehicle, excipient, or diluent.

USSN: 10/743,109

- 17 -

PC20612A

Claim 26 (original): A pharmaceutical composition comprising a compound of claim 1, 8, 17, 19, 20, 22, or 24 and further comprising a second therapeutic agent.

Claim 27 (original): A method for treating or preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancretitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder, modulating C reactive protein, or enhancing bile production in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 28 (original): A method for treating or preventing cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 29 (original): A method for treating or preventing a dyslipidemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically, or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 30 (original): A method for treating or preventing a dyslipoproteinemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 31 (original): A method for treating or preventing a disorder of glucose metabolism in a patient, comprising administering to a patient in need of such treatment or

USSN: 10/743,109

- 18 -

PC20612A

prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 32 (original):** A method for treating or preventing a Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 33 (original):** A method for treating or preventing Syndrome X in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 34 (original):** A method for treating or preventing a septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 35 (original):** A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 36 (original):** A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

**Claim 37 (original):** A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

USSN: 10/743,109

- 19 -

PC20612A

Claim 38 (original): A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 39 (original): A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 40 (original): A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 41 (original): A method for treating or preventing cancer in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 42 (original): A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 43 (original): A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

Claim 44 (original): A method for treating or preventing a neurodegenerative disease or disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.

USSN: 10/743,109

- 20 -

PC20612A

**Claim 45 (original): A method of inhibiting hepatic fatty acid synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.**

**Claim 46 (original): A method of inhibiting sterol synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.**

**Claim 47 (original): A method of treating or preventing metabolic syndrome disorders in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.**

**Claim 48 (original): A method of treating or preventing a disease or disorder that is capable of being treated by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.**

**Claim 49 (original): A method of treating or preventing a disease or disorder that is capable of being treated by lowering LDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, 8, 17, 19, 20, 22, or 24.**


**Claim 50 (original): A pharmaceutical composition comprising a compound of claim 1, 8, 17, 19, 20, 22, 24, or 26 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.**

**Claim 51 (new): A compound according to claim 1 wherein said compound has the structure:**

USSN: 10/743,109


- 21 -

PC20612A

**6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid;**


or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

**Claim 52 (new): A compound according to claim 1 wherein said compound has the structure:**

**2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol;**

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

**Claim 53 (new): A compound according to claim 1 wherein said compound has the structure:**

**6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid;**

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

**Claim 54 (new): A compound according to claim 1 wherein said compound has the structure:**

**2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol.;**

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.